INTERNATIONAL AIDS VACCINE INITIATIVE INC. - THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN

On Oct 29, 2025, Department of Health and Human Services obligated $95,592,504 to INTERNATIONAL AIDS VACCINE INITIATIVE INC. for the overall objective of this contract is to advance the development of monovalent vaccines for prevention of marburg virus (marv) and sudan ebolavirus (sudv) disease. these vaccines are based on rec…. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in NEW YORK, NY. The contract is scheduled through Nov 30, 2027 — approximately 18 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.